Developing a Knowledge Graph Framework for Pharmacokinetic Natural Product-Drug Interactions

  title={Developing a Knowledge Graph Framework for Pharmacokinetic Natural Product-Drug Interactions},
  author={Sanya Bathla Taneja and Tiffany J. Callahan and Mary F. Paine and Sandra L. Kane-Gill and Halil Kilicoglu and marcin p. joachimiak and Richard David Boyce},
Background : Pharmacokinetic natural product-drug interactions (NPDIs) occur when botanical or other natural products are co-consumed with pharmaceutical drugs. With the growing use of natural products, the risk for potential NPDIs and consequent adverse events has increased. Understanding mechanisms of NPDIs is key to preventing or minimizing adverse events. Although biomedical knowledge graphs (KGs) have been widely used for drug-drug interaction applications, computational investigation of… 



Discovering novel drug-supplement interactions using SuppKG generated from the biomedical literature

A semantic knowledge-base approach to drug-drug interaction discovery

A novel, semantic-reasoning-based approach to look for potentially adverse drug-drug interactions (DDIs) by using a knowledge-base of biomedical public ontologies and datasets in a semantic graph representation to find previously unknown relations between different biological entities like drugs, proteins and biological processes.

A novel graph mining approach to predict and evaluate food-drug interactions

FDMine, a novel systematic framework that models the FDI problem as a homogenous graph, is proposed and validated to demonstrate its applicability, and it is related to therapeutic anti-inflammatory effects of food items informed by FDIs.

Contexts and contradictions: a roadmap for computational drug repurposing with knowledge inference

Challenges to creating literature-scale representations of pharmacological knowledge are described and current approaches toward incorporating context and resolving contradictions are surveyed.

A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies

The NaPDI Center repository is the first user-friendly online repository that stores data from in vitro and clinical pharmacokinetic NPDI experiments and links them with study data from chemical characterization and metabolomics analyses of natural products that are also stored in the repository.

Modeling Pharmacokinetic Natural Product–Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach

A framework for developing and applying pharmacokinetic NPDI models is presented with the aim of promoting accuracy, reproducibility, and generalizability in the literature.

Herb–Drug Interactions: Challenges and Opportunities for Improved Predictions

Integration of in silico models that estimate the pharmacokinetics of individual constituents should facilitate prospective identification of herb–drug interactions and help provide definitive information to both consumers and clinicians about the risk of adding herbal products to conventional pharmacotherapeutic regimens.

Systematic integration of biomedical knowledge prioritizes drugs for repurposing

The ability to computationally predict whether a compound treats a disease would improve the economy and success rate of drug approval and provide pharmacological insights on epilepsy are described, suggesting they will help prioritize drug repurposing candidates.

A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information

DTINet is introduced, whose performance is enhanced in the face of noisy, incomplete and high-dimensional biological data by learning low-dimensional vector representations, which accurately explains the topological properties of individual nodes in the heterogeneous network.

Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary

The NaPDI Center has two overarching goals: develop Recommended Approaches to guide researchers in the proper conduct of NPDI studies, which will evolve over time concurrent with emerging technologies and new research data, and apply the recommended approaches in evaluating four model NPs as precipitants of N PDIs with clinically relevant object drugs.